Healthcare

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label…

6 months ago

Halo Dental Technologies Showcase Their Digital Mirror at Montreal-based JDIQ Annual Conference

At the largest bilingual dental convention in North America, Halo will showcase the first-of-its-kind digital dental mirror at its home-city…

6 months ago

FSD Pharma Provides Corporate Update

TORONTO, ON / ACCESSWIRE / May 24, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…

6 months ago

Cosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of Its Forms 10-K and 10-Q

CHICAGO, IL / ACCESSWIRE / May 24, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

6 months ago

TruBridge Announces Participation in the Stifel Cross Sector Insight Conference

MOBILE, Ala.--(BUSINESS WIRE)--TruBridge, Inc. (NASDAQ:TBRG), a healthcare solutions company, today announced that management will participate in the Stifel Cross Sector…

6 months ago

GRM Information Management to Attend the 2024 MUSE Inspire Conference

Visit GRM Information Management in Booth #125 at the 2024 MUSE Inspire Conference in Denver, CO May 28-31JERSEY CITY, N.J.--(BUSINESS…

6 months ago

Stereotaxis Receives CE Mark Recertification Under EU’s MDR Regulatory Framework

ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for…

6 months ago

Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024

Press Release Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024May 24, 2024 – release at 7:30…

6 months ago

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or…

6 months ago

Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting

Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and CollaboratorsSALT…

6 months ago